Odenthal, Germany

Bettina Rohde

This inventor holds 1 USPTO granted patent. Top assignee: Bayer Aktiengesellschaft. Active years: 2002.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Bettina Rohde: Innovator in Oral Pharmaceutical Preparations

Introduction

Bettina Rohde is a notable inventor based in Odenthal, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of oral preparations. His innovative work has led to the creation of a unique formulation that enhances the delivery of active compounds.

Latest Patents

Bettina Rohde holds a patent for "Semi-solid aqueous preparations for oral applications of toltrazuril sulphone." This invention relates to orally administrable pastes of toltrazuril sulfone, comprising an active compound in a concentration of 0.1-20% by weight. The formulation features a particle size ranging from 1 to 10 micrometers, polyacrylic acids with a degree of polymerization of about 3, and a concentration of 0.1-5% by weight. Additionally, the preparation may include preservatives and moisturizers, with the remainder being water, totaling 100% by weight.

Career Highlights

Bettina Rohde is associated with Bayer Aktiengesellschaft, a leading global company in the pharmaceutical and life sciences sector. His work at Bayer has allowed him to focus on innovative solutions that address the needs of patients and healthcare providers.

Collaborations

Throughout his career, Bettina has collaborated with esteemed colleagues such as Hans-Christian Mundt and Matthias Kuhn. These partnerships have fostered a creative environment that encourages the development of groundbreaking pharmaceutical solutions.

Conclusion

Bettina Rohde's contributions to the field of oral pharmaceutical preparations exemplify the impact of innovation in healthcare. His patent for toltrazuril sulphone formulations showcases his commitment to improving patient outcomes through effective drug delivery systems.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…